Programs in Development:
Broad-based pipeline of unique acute and chronic care pharmacologic and device programs
Critical care and underserved acute and chronic medical conditions
Stephen J. Petti, CEO
Laurence M. Katz, MD, CSO
Pia Mikkelsen Lynch, MD, CMO
Kathryn Martin, PharmD., DD
Melisa Barron, PhD., CMC
Sydney Gilman, PhD., RA
Samn Raffaniello, Proj Svcs
Hibernaid is a privately held company developing unique drugs and devices for important acute medical indications in high-risk critical care patient populations, as well as unique treatments targeting underserved chronic indications.
The Company's lead development compound is HBN-1, a unique IV combination drug that pharmaceutically induces clinically-relevant regulated hypothermia (deliberate reduction of core body temperature) to prevent neurological, functional and organ damage and significantly increase the probability of survival in a broad range of acute care medical conditions.
HBN-1 is initially being developed for use in resuscitated post-cardiac arrest patients but the technology will also be developed for the treatment of stroke, traumatic brain injury, spinal cord injury and other acute critical care indications.
The Company is also developing important new drugs and devices to treat a variety of medical indications, most notably severe sepsis and septic shock (critical care), as well as mild concussion (including sports related injuries), Progeria, an orphan indication that causes premature aging and early death in children and menopausal-related 'hot flashes'.